Senti Bio secures additional $11.5M from PIPE closing and CIRM grant; cash runway into 2026

Senti Biosciences, Inc.

Closed subsequent PIPE closing with Celadon Partners for additional ~$10M gross proceeds (4,444 Series A shares + warrants for 6,666,000 common shares); total PIPE now $47.6M.
Received $1.5M from CIRM grant; total received $6.4M of $8M grant announced June 2024.
Cash runway guidance extended into 2026; proceeds to fund SENTI-202 development and manufacturing.
Securities sold under Section 4(a)(2)/Rule 506 exemption; registration rights agreement for resale filed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.